Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve

Eli Lilly (LLY) dropped 8% last month despite 48% revenue growth, leaving Citi's $1,600 Street-high target implying 45% upside.

Novo Nordisk (NVO) offers only ~10% analyst upside and Merck (MRK) just ~6%, making Lilly the clear outlier for implied returns across pharma peers.

Retatrutide showed bariatric-surgery-level weight loss in trials, with a BLA filing planned for Q1 2027 and oral GLP-1 Foundeo jumping from 8,000 to 36,000 prescribers in one quarter.

Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.

Eli Lilly ( NYSE:LLY ) recently closed at $1,114.90, while the average Wall Street 12-month price target sits at $1,318.66. Citi is far more aggressive, carrying a Street-high $1,600 target that implies roughly 45% upside from here.

Eli Lilly is the runaway leader in the GLP-1 obesity and diabetes market, with Mounjaro and Zepbound now doing roughly $14.9 billion in combined quarterly revenue. It is also a diversified pharma with more than 40 active phase three programs across oncology, immunology and neuroscience.

Wall Street has been paying close attention because Lilly is one of the largest weight-loss stories in market history, and the recent pullback has opened a rare gap between where the stock trades and where analysts think it belongs.

Lilly dropped 8.44% over the past month, sliding from $1,218.49 to $1,115.70. That is a real air pocket in a stock this heavy, and it happened against an S&P 500 that only fell 1.06% over the same window. The selloff was clearly company and sector specific.